Patents by Inventor Matyas GORJANACZ

Matyas GORJANACZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230250178
    Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.
    Type: Application
    Filed: June 25, 2021
    Publication date: August 10, 2023
    Inventors: Sandra BERNDT, Katharina FILARSKY, Philipp ELLINGER, Beatrix STELTE-LUDWIG, Sabine HOFF, Helge ROIDER, Ernst WEBER, Mark TRAUTWEIN, Christian VOTSMEIER, Nikolaus PAWLOWSKI, Uwe GRITZAN, Pascale BUCHMANN, Christian BERTLING, Oliver VON AHSEN, Wiebke Maria NADLER, Su-Yi TSENG, Pedro PAZ, Phaik Lyn OH, Patrick JONES, Matyas GORJANACZ
  • Publication number: 20230113037
    Abstract: The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 10, 2020
    Publication date: April 13, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Julien LEFRANC, Norbert SCHMEES, Ludwig ZORN, Robin Michael MEIER, Simon Anthony HERBERT, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Mátyás GORJÁNÁCZ, Christina KOBER, Bernd BUCHMANN, Stephan BÖHME, Ulrich BOTHE, Michael PLATTEN, Daniel BAUMANN
  • Publication number: 20220226279
    Abstract: The present invention provides acyl sulfonamide compounds of general formula (I): in which X, R1, R2, R3, R4, R5, R6? Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treating and/or prophylaxing diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.
    Type: Application
    Filed: April 20, 2020
    Publication date: July 21, 2022
    Inventors: Léa Aurelie Bouché, Daniel Korr, Antonius ter Laak, Ernesto Amaury Fernandez-Montalvan, Naomi Barak, Roman Hillig, Roland Neuhaus, Matyas Gorjanacz, Vera Pütter, Stefan Niklaus Gradl, Simon Anthony Herbert, Steven James Ferrara, Craig Strathdee, Jacob Jaffe
  • Patent number: 10654818
    Abstract: The invention relates to furane derivatives of formula (I) as inhibitors of ATAD2, a process for their preparation and use thereof.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: May 19, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Markus Berger, Jan Hübner, Antonius Ter Laak, Matyas Gorjanacz, Amaury Ernesto Fernandez-Montalvan, Vincent Rodeschini, Didier Roche
  • Publication number: 20190218196
    Abstract: The invention relates to furane derivatives of formula (I) as inhibitors of ATAD2, a process for their preparation and use thereof.
    Type: Application
    Filed: November 30, 2016
    Publication date: July 18, 2019
    Inventors: Markus BERGER, Jan HÜBNER, Antonius TER LAAK, Matyas GORJANACZ, Amaury Ernesto FERNANDEZ-MONTALVAN, Vincent RODESCHINI, Didier ROCHE